DrugPatentWatch Database Preview
Drugs in Development Information for CORT118335
» See Plans and Pricing
What is the development status for investigational drug CORT118335?
CORT118335 is an investigational drug.
There have been 8 clinical trials for CORT118335.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2019.
The most common disease conditions in clinical trials are Weight Gain, Schizophrenia, and Non-alcoholic Fatty Liver Disease. The leading clinical trial sponsors are Corcept Therapeutics, The Scripps Research Institute, and National Institute on Alcohol Abuse and Alcoholism (NIAAA).
There are five US patents protecting this investigational drug and fifty-four international patents.
Summary for CORT118335
| US Patents | 5 |
| International Patents | 54 |
| US Patent Applications | 8 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2019-03-01) |
| Vendors | 5 |
Recent Clinical Trials for CORT118335
| Title | Sponsor | Phase |
|---|---|---|
| Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 |
| Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo | The Scripps Research Institute | Phase 2 |
| Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II) | Corcept Therapeutics | Phase 2 |
Clinical Trial Summary for CORT118335
Top disease conditions for CORT118335
Top clinical trial sponsors for CORT118335
US Patents for CORT118335
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CORT118335 | Start Trial | Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome | Corcept Therapeutics, Inc. (Menlo Park, CA) | Start Trial |
| CORT118335 | Start Trial | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | Corcept Therapeutics, Inc. (Menlo Park, CA) | Start Trial |
| CORT118335 | Start Trial | Pyrimidine cyclohexyl glucocorticoid receptor modulators | Corcept Therapeutics, Inc. (Menlo Park, CA) | Start Trial |
| CORT118335 | Start Trial | Pyrimidine cyclohexyl glucocorticoid receptor modulators | Corcept Therapeutics, Inc. (Menlo Park, CA) | Start Trial |
| CORT118335 | Start Trial | Pyrimidine cyclohexyl glucocorticoid receptor modulators | Corcept Therapeutics, Inc. (Menlo Park, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CORT118335
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CORT118335 | Australia | AU2017210156 | 2036-01-19 | Start Trial |
| CORT118335 | Canada | CA3011728 | 2036-01-19 | Start Trial |
| CORT118335 | European Patent Office | EP3405101 | 2036-01-19 | Start Trial |
| CORT118335 | Japan | JP2019503495 | 2036-01-19 | Start Trial |
| CORT118335 | South Korea | KR20180096803 | 2036-01-19 | Start Trial |
| CORT118335 | Mexico | MX2018008849 | 2036-01-19 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
